Dr Anilkumar Parambath is Senior R&D Manager of YTY Group, Indorama Corp., Perak, Malaysia. Prior to this, he was R&D Manager, Science & Technology at Unilever (2021-2024); Senior Manager and Head of Capsules Product R&D, ACG Capsules, Mumbai, India (2018-2021) and Principal Investigator for Performance and Specialty Materials at Syngene International Ltd, Bangalore India (2017-2018), where he worked on developing various elastomers, silicones, acrylics and other polymers for biomedical applications. He completed his PhD in Chemistry (Polymer Science) at the University of Kerala, India, and spent 7 years conducting post-doctoral research at Clemson University, USA, French atomic Energy Commission (CEA), France, and the University of British Columbia, Canada. HIs expertise is in polymer science, materials science, green chemistry, nanotechnology, nanomedicine, and biomaterials science. Dr. Parambath has edited three books on polymer biomaterials in drug delivery applications, including two with Elsevier, and has published many books chapters and journal articles. He has two patents to his name. In 2024, he was recognized by the American Chemical Society (ACS) as a Sustainability Star.

• 1. PEGylated ‘stealth’ liposomes2. PEGylated proteins3. PEGylation and anti-PEG antibodies 4. Poly (zwitterions) 5. Poly (glycerols)6. Poly (oxazolines)7. Poly (aminoacids)8. Poly (acylamides) and related systems9. Poly (vinylpyrrolidones)10. Sugar based systems (trehalose)11. Polypeptide alternatives (PASylation and XTen) to PEG 12. DDS based on non-immunogenic biopolymers13. Non-PEGylated nanoparticles 14. Summary and future perspectives

Dr Anilkumar Parambath is Senior R&D Manager of YTY Group, Indorama Corp., Perak, Malaysia. Prior to this, he was R&D Manager, Science & Technology at Unilever (2021-2024); Senior Manager and Head of Capsules Product R&D, ACG Capsules, Mumbai, India (2018-2021) and Principal Investigator for Performance and Specialty Materials at Syngene International Ltd, Bangalore India (2017-2018), where he worked on developing various elastomers, silicones, acrylics and other polymers for biomedical applications. He completed his PhD in Chemistry (Polymer Science) at the University of Kerala, India, and spent 7 years conducting post-doctoral research at Clemson University, USA, French atomic Energy Commission (CEA), France, and the University of British Columbia, Canada. HIs expertise is in polymer science, materials science, green chemistry, nanotechnology, nanomedicine, and biomaterials science. Dr. Parambath has edited three books on polymer biomaterials in drug delivery applications, including two with Elsevier, and has published many books chapters and journal articles. He has two patents to his name. In 2024, he was recognized by the American Chemical Society (ACS) as a Sustainability Star.

• 1. PEGylated ‘stealth’ liposomes2. PEGylated proteins3. PEGylation and anti-PEG antibodies 4. Poly (zwitterions) 5. Poly (glycerols)6. Poly (oxazolines)7. Poly (aminoacids)8. Poly (acylamides) and related systems9. Poly (vinylpyrrolidones)10. Sugar based systems (trehalose)11. Polypeptide alternatives (PASylation and XTen) to PEG 12. DDS based on non-immunogenic biopolymers13. Non-PEGylated nanoparticles 14. Summary and future perspectives

Dr Anilkumar Parambath is Senior R&D Manager of YTY Group, Indorama Corp., Perak, Malaysia. Prior to this, he was R&D Manager, Science & Technology at Unilever (2021-2024); Senior Manager and Head of Capsules Product R&D, ACG Capsules, Mumbai, India (2018-2021) and Principal Investigator for Performance and Specialty Materials at Syngene International Ltd, Bangalore India (2017-2018), where he worked on developing various elastomers, silicones, acrylics and other polymers for biomedical applications. He completed his PhD in Chemistry (Polymer Science) at the University of Kerala, India, and spent 7 years conducting post-doctoral research at Clemson University, USA, French atomic Energy Commission (CEA), France, and the University of British Columbia, Canada. HIs expertise is in polymer science, materials science, green chemistry, nanotechnology, nanomedicine, and biomaterials science. Dr. Parambath has edited three books on polymer biomaterials in drug delivery applications, including two with Elsevier, and has published many books chapters and journal articles. He has two patents to his name. In 2024, he was recognized by the American Chemical Society (ACS) as a Sustainability Star.

• 1. PEGylated ‘stealth’ liposomes2. PEGylated proteins3. PEGylation and anti-PEG antibodies 4. Poly (zwitterions) 5. Poly (glycerols)6. Poly (oxazolines)7. Poly (aminoacids)8. Poly (acylamides) and related systems9. Poly (vinylpyrrolidones)10. Sugar based systems (trehalose)11. Polypeptide alternatives (PASylation and XTen) to PEG 12. DDS based on non-immunogenic biopolymers13. Non-PEGylated nanoparticles 14. Summary and future perspectives